Cyclopharm is an established Australian radiopharmaceutical company servicing the global medical community since 1986.
Cyclopharm is a company in the diagnostic imaging field specialising in lung health. We achieve this positioning through our proprietary medical device and pharmaceutical products under the name of TECHNEGASTM.
TECHNEGASTM has become the industry gold-standard in diagnostic functional lung imaging technology.
We distribute our products in 57 countries throughout the world with over 1500 nuclear medicine departments utilising TECHNEGASTM.
To date, over 4.2 million patient procedures are recorded.
Market Reports /
by Melissa Darmawan -
4 years ago
05 Feb 2021 - It has been a positive day of trade for the Australian share market. After opening higher, it continued its momentum to close the week off strong. At the closing bell…
Interviews /
by Melissa Darmawan -
4 years ago
29 Jan 2021 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about the company's recent cap raising to support rapid USA commercialisation for Technegas followi…
Market Reports /
by Melissa Darmawan -
4 years ago
14 Jan 2021 - It has been a positive day of trade for the ASX. After opening higher, the market slightly dipped and then rallied throughout the day to end 0.4% higher. Over in the …
Company Presentations /
by -
4 years ago
11 Dec 2020 - Cyclopharm Limited (ASX:CYC) CEO and Managing Director James McBrayer provides an overview of the company, discussing pulmonary embolism and Technegas, competitor pro…
Interviews /
by Melissa Darmawan -
4 years ago
11 Dec 2020 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director James McBrayer talks about USFDA approval for Technegas, the company's USA commercialisation plan, and opportunit…
Interviews /
by Rachael Jones -
4 years ago
28 Sep 2020 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO James McBrayer provides an update on the company's US Phase 3 trial for Technegas, and USFDA approval process t…
Market Reports /
by Rachael Jones -
4 years ago
09 Sep 2020 - After a fall at the open the ASX failed to recover closing 2.2% lower. Shares in Nufarm (ASX:NUF) closed up today, meanwhile, shares in Beach Energy took a hit fallin…
Company News /
by Rachael Jones -
4 years ago
09 Sep 2020 - Cyclopharm (ASX:CYC) today announced a new research collaboration with McMasters University and other industry leaders aimed at understanding the short- term and long…
Interviews /
by Anna Napoli -
4 years ago
03 Jun 2020 - Cyclopharm (ASX:CYC) Managing Director and CEO James McBrayer provides an update on US FDA progress with Technegas, approval in Russia and potential use of Technegas …
Market Reports /
by Rachael Jones -
5 years ago
14 Apr 2020 - It has been a mostly positive day of trade for the ASX after a small dip in early morning trade the local bourse managed to close 1.9% higher. As for the sectors toda…
Company News /
by Rachael Jones -
5 years ago
14 Apr 2020 - Cyclopharm (ASX:CYC) is pleased to announce that the United States Food and Drug Administration (USFDA) has granted the Company a full application fee waiver of USD $…
Interviews /
by Rachael Jones -
5 years ago
06 Apr 2020 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its new drug application with the US FDA for Technegas and applications beyond pulmonary embo…
Market Reports /
by Rachael Jones -
5 years ago
30 Mar 2020 - It has been a mostly positive day of trade for the ASX after managing to gain momentum the local bourse managed to close 7% higher. Mayne Pharma (ASX:MYX) shares saw …
Interviews /
by Rachael Jones -
5 years ago
23 Dec 2019 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO, James McBrayer talks about the company's joint venture to expand Positron Emission Tomography (PET) diagnostic…
Market Reports /
by Katrina Bullock -
6 years ago
05 Apr 2019 - Australian shares are poised to open lower this morning following mixed leads from Wall Street. Tensions around the US/China trade deal continue as President Donald T…
Interviews /
by Jessica Amir -
6 years ago
29 Oct 2018 - Cyclopharm Limited (ASX:CYC) Managing Director and CEO, James McBrayer talks about the company's meeting with the US FDA for approval of Technegas, timelines and next…
Company Presentations /
by -
6 years ago
26 Sep 2018 - Cyclopharm (ASX:CYC) Managing Director & CEO, James McBrayer presents an update on its radiopharmaceutical products used in imaging, sales of Technegas and its US FDA…
Interviews /
by Rachael Jones -
6 years ago
26 Sep 2018 - Cyclopharm (ASX:CYC) Managing Director & CEO, James McBrayer provides an update on its radiopharmaceutical products used in imaging, sales of Technegas and its US FDA…
Market Reports /
by Rachael Jones -
7 years ago
06 Apr 2018 - The Australian share market looks set to open higher this morning - albeit only slightly. Wall Street closed higher with the Dow rising 1 per cent with the likes of D…
Company Presentations /
by -
7 years ago
18 Dec 2017 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director James McBrayer talks 1H17 Results, Technegas adoption and US FDA trial progress.
Interviews /
by Jessica Amir -
7 years ago
18 Dec 2017 - Cyclopharm Limited (ASX:CYC) CEO & Managing Director, James McBrayer provides an update on the company's Technegas lung imaging technology, sales and US regulatory ti…
Company News /
by David Murdoch -
7 years ago
19 Sep 2017 - Cyclopharm (ASX:CYC), has joined forces with Cyclotek and PETTECH Solutions in an effort to advance the Australian molecular imaging sector.
Market Reports /
by Jessica Amir -
7 years ago
18 Aug 2017 - Barcelona & Wall St tolls: ASX200 0.89% lower at noon. Cocoa-Cola Amatil (ASX:CCL) says it’s planning to recover the fees from the NSW Container Deposit Scheme by pas…
Market Reports /
by David Chau -
8 years ago
28 Jun 2016 - Aus shares set to open lower. Cyclopharm Ltd (ASX:CYC) enters strategic partnership with the Canadian Association of Nuclear Medicine.
